Evaluation of Benign Joint Hypermobility and Serum Prolidase Levels in Children Diagnosed With Attention-Deficit/Hyperactivity Disorder (ADHD) Compared to Healthy Controls
Key facts
- Who runs it
- Antalya Training and Research Hospital
- Where
- Türkiye1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 171 people enrolled
- Started
- 1 Apr 2025
- Ended
- 11 Oct 2025
- Type of study
- Observational, 2 groups
- Record updated
- 23 June 2026
Who can take part
- Age
- 6 years to 12 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (11)Hide the full registry criteria
Who can take part
- Children aged between 6 and 12 years
- ADHD diagnosis based on DSM-5 criteria (for patient group)
- Healthy children with no known psychiatric or systemic disease (for control group)
- Willingness of the parents or legal guardians to participate and provide informed consent
- Ability to complete the required clinical assessments (CPRS-R:S, Beighton Score, blood sample)
Who cannot take part
- Use of medications that may affect prolidase enzyme activity (e.g., corticosteroids, immunosuppressants)
- Presence of chronic systemic diseases (e.g., autoimmune disorders, connective tissue diseases, metabolic syndromes)
- History of neurodegenerative or severe neurological disorders Intellectual disability or autism spectrum disorder diagnosis
- Any orthopedic or musculoskeletal condition interfering with Beighton assessment
- Incomplete clinical or laboratory data
- Refusal to participate or lack of parental consent
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This cross-sectional observational study investigates the clinical and biochemical relationship between Attention-Deficit/Hyperactivity Disorder (ADHD) and Benign Joint Hypermobility Syndrome (BJHS) in pediatric patients. The primary objective is to evaluate the prevalence of BJHS in children diagnosed with ADHD and compare serum prolidase levels with those of healthy controls. The study also explores whether the severity of ADHD symptoms correlates with serum prolidase activity. Clinical assessments include the Conners Parent Rating Scale, Beighton Score, and serum prolidase measurement using ELISA. This research aims to provide new insights into the potential connective tissue-neurodevelopmental link and contribute to early screening frameworks for children with ADHD.
The 2 groups in the trial
- Group 1 Name: ADHD Group Type: Observational Cohort
Children aged 6 to 12 years who were clinically diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD) according to DSM-5 criteria. Participants in this cohort were recruited from the Child and Adolescent Psychiatry outpatient clinic of Antalya Training and Research Hospital. Each child underwent a detailed clinical evaluation including the Conners' Parent Rating Scale-Revised: Short Form (CPRS-R:S) to determine ADHD symptom severity and subtype. Joint hypermobility was assessed using the Beighton Score, and venous blood samples were collected to measure serum prolidase enzyme activity using ELISA. No therapeutic intervention was applied; this is a non-interventional observational group.
- Group 2 Name: Control Group Type: Observational Cohort
This group consisted of age- and sex-matched healthy children between 6 and 12 years of age with no history of psychiatric, neurological, or systemic illness. Control participants were selected from the general pediatric outpatient population and underwent the same evaluations as the ADHD group. These included the Conners' Parent Rating Scale-Revised: Short Form (CPRS-R:S), Beighton Score assessment for joint hypermobility, and serum prolidase measurement via ELISA. The purpose of this group was to provide a baseline comparison for clinical and biochemical parameters without any intervention applied.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 23 June 2026